Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772998 | 0.88 | MT-CO2 (0.38) | MT-CO2NR1H2 | |
| SCHEMBL3778075 | 0.82 | TP53 (0.31) | — | |
| SCHEMBL17894521 | 0.81 | MIF (0.36) | MT-CO2 | |
| SCHEMBL3777967 | 0.81 | SCN2A (0.32) | MT-CO2 | |
| SCHEMBL3785117 | 0.79 | KMT2A (0.34) | — | |
| SCHEMBL15876020 | 0.79 | MAPT (0.39) | — | |
| SCHEMBL3775825 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL15140038 | 0.77 | F2 (0.35) | — | |
| SCHEMBL207903 | 0.76 | MTNR1B (0.35) | NR1H2 | |
| SCHEMBL7797012 | 0.76 | UNG (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2010-12-30 | — | — | US | disclosed |
| WO-2009080818-A2 | GUANIDINE BASED COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | ADRB2, ADRA2A, ADRA2C | MT-CO2 2178/4885NR1H2 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.